The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISAL 2019 | Use of gemtuzumab ozogamicin in CBF-AML
Alan Burnett
• 1 Mar 2019
Alan Burnett, MD, FRCP, of Cardiff University, Cardiff, UK, discusses the clinical development of gemtuzumab ozogamicin, focusing on its use in core binding factor (CBF) acute myeloid leukemia (AML) and the remaining questions in this field. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.
